KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLoans and Notes ReceivablesLong-Term Debt IssuancesNon-Current ReceivablesReceivables RefundsShares Repurchased
Ratios

Royalty Pharma (RPRX) Receivables Refunds (2019 - 2025)

Royalty Pharma's Receivables Refunds history spans 7 years, with the latest figure at $29.3 million for Q4 2025.

  • For Q4 2025, Receivables Refunds rose 8.76% year-over-year to $29.3 million; the TTM value through Dec 2025 reached $29.3 million, up 8.76%, while the annual FY2025 figure was $29.3 million, 8.76% up from the prior year.
  • Receivables Refunds for Q4 2025 was $29.3 million at Royalty Pharma, up from $28.9 million in the prior quarter.
  • Across five years, Receivables Refunds topped out at $29.3 million in Q4 2025 and bottomed at $6.5 million in Q1 2021.
  • The 5-year median for Receivables Refunds is $21.8 million (2023), against an average of $20.5 million.
  • The largest annual shift saw Receivables Refunds skyrocketed 239.82% in 2021 before it rose 0.65% in 2024.
  • A 5-year view of Receivables Refunds shows it stood at $15.0 million in 2021, then skyrocketed by 31.58% to $19.8 million in 2022, then grew by 13.35% to $22.4 million in 2023, then rose by 20.31% to $27.0 million in 2024, then grew by 8.76% to $29.3 million in 2025.
  • Per Business Quant, the three most recent readings for RPRX's Receivables Refunds are $29.3 million (Q4 2025), $28.9 million (Q3 2025), and $27.7 million (Q2 2025).